Certara Drug Development & Regulatory Experts Achieve 100th Rare Disease Submission Blog Post
Dedicated team of global regulatory experts drives the approval of rare disease treatments RADNOR, Pa. — 2024 年 10 月 1 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug…
How to Use CDISC’s ODM Standard for CRF Design Blog Post
Over the last decade, our industry has become familiar with Clinical Data Interchange Standards Consortium (CDISC) standards. This has largely been driven by regulation, with national regulators such as FDA…
How Clinical Trial Technology Streamlines the Research Process Blog Post
Learn how innovative clinical trial technology helps to revolutionize research & ensure the swift rollout of safe and effective treatments.
Certara’s Simcyp Consortium Celebrates 25th Anniversary Blog Post
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and regulatory decisions RADNOR, PA –…
Why cancer drug programs need human mass balance studies Blog Post
传统上，肿瘤学及其他快速致命疾病药物研发项目未将质量平衡研究纳入临床药理学研究包。This omission stems from the ICH S9 on nonclinical evaluation…
Certara Launches Early Development Solution to Reduce Failure Rates in Early-Stage Drug Development Blog Post
New solution offers early-stage developers a dedicated team of experts with combined experience in end-to-end drug development to optimize delivery timelines, derisk programs, and improve outcomes. RADNOR, PA – SEPTEMBER…
